NMTC NEUROONE MEDICAL TECHNOLOGIES CORP

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update.

Conference Call and Webcast Information:

Tuesday, February 13, 2024 – 4:30 PM Eastern Time

Participant Dial-In:

888-506-0062 /

Access Code:

540724

Live Webcast: 

        

Phone Replay:

877-481-4010/

Available through February 27, 2024

Webcast Replay:        

Available for 12 months

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit .

Contact:

800-631-4030



EN
08/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROONE MEDICAL TECHNOLOGIES CORP

 PRESS RELEASE

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Re...

NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025. Recent Company...

 PRESS RELEASE

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:3...

 PRESS RELEASE

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results o...

NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Ea...

 PRESS RELEASE

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent...

NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, “Methods for Making Probe...

 PRESS RELEASE

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Foll...

NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System Patient Treated with OneRF® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara—an early patient treated with the Company’s patented OneRF® Ablation System—has successf...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch